Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016

Keyphrases

• European Consensus 100%
• Consensus-based 100%
• Metastatic Melanoma 100%
• Melanoma Treatment 100%
• Guideline Update 100%
• Melanoma Detection 100%
• Oncology 50%
• Cancer Mortality 50%
• MEK Inhibitor (MEKi) 50%
• Systemic Treatment 50%
• Adjuvant Therapy 50%
• Distant Metastasis 50%
• Cancer Treatment 50%
• Overall Survival Time 50%
• Survival Benefit 50%
• Systematic Literature Review 50%
• Melanoma 50%
• Skin Cancer 50%
• Therapeutic Decision-making 50%
• Tumor Board 50%
• Patient with Tumor 50%
• Staging Procedures 50%
• Disease-free Survival 50%
• European Organizations 50%
• Surgical Therapy 50%
• Trametinib 50%
• Vemurafenib 50%
• Dabrafenib 50%
• BRAF Inhibitor (BRAFi) 50%
• Interferon Treatment 50%
• Second-line Treatment 50%
• CTLA-4 Inhibitors 50%
• European Associations 50%
• Skin Tumor 50%
• Dermato-oncology 50%
• Surgical Options 50%
• Safety Margin 50%
• BRAF Wild Type 50%
• Cobimetinib 50%
• Anti-PD-1 Antibody 50%
• Expert Experience 50%
• Sentinel Lymph Node Dissection 50%
• Dermoscopy 50%

Medicine and Dentistry

• Neoplasm 100%
• Oncology 100%
• Cutaneous Melanoma 100%
• Melanoma 100%
• Cancer Mortality 50%
• Overall Survival 50%
• Surgery 50%
• Systemic Therapy 50%
• Immunotherapy 50%
• Systematic Review 50%
• Distant Metastasis 50%
• Cancer Treatment 50%
• Adjuvant Therapy 50%
• Skin Cancer 50%
• Survival Time 50%
• Retroperitoneal Lymph Node Dissection 50%
• Disease Free Survival 50%
• Vemurafenib 50%
• Interferon 50%
• Trametinib 50%
• MEK Inhibitor 50%
• Cytotoxic T Lymphocyte Antigen 4 Antibody 50%
• Dabrafenib 50%
• Skin Tumor 50%
• Dermatoscopy 50%
• Sentinel Lymph Node 50%
• Dermatology 50%
• Cobimetinib 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Melanoma 100%
• Cutaneous Melanoma 100%
• Malignant Neoplasm 50%
• Overall Survival 50%
• Cancer Mortality 50%
• Distant Metastasis 50%
• Interferon 50%
• Systemic Treatment 50%
• Immunotherapy 50%
• Disease Free Survival 50%
• Vemurafenib 50%
• Survival Time 50%
• Skin Cancer 50%
• Dabrafenib 50%
• Skin Tumor 50%
• Trametinib 50%
• Mitogen Activated Protein Kinase Kinase Inhibitor 50%
• Cytotoxic T Lymphocyte Antigen 4 Antibody 50%
• Cobimetinib 50%